Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chatbot could put blood pressure control in Patients' hands

NCT ID NCT06845007

Knowledge-focused Sponsor: Ana Rita Londral Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study is testing a chatbot platform called PROMBot that lets people with hypertension report their blood pressure and other health information via text messages. The goal is to see if the chatbot is easy and enjoyable to use, and whether it can help patients stay engaged in their own care. Researchers will interview participants about their experiences and track how often they interact with the chatbot.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A web-based chatbot platform for collecting patient-reported outcomes and providing medication reminders and healthy habit tips
What this could lead to
If successful, this chatbot could offer a simple, engaging way for people with hypertension to track their blood pressure and stay on top of their care, potentially improving follow-up and self-management.
What could go wrong
This is a small, early-stage study focused on user experience, not on health outcomes. The chatbot may not be widely adopted or may not lead to measurable improvements in blood pressure control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

24 people

The number who actually took part.

Started

Jan 2025

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All study participants must have hypertension, live in Portugal and be followed by a doctor at the CUF hospital.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged between 18 and 75 years old. * Diagnosed with hypertension, based on ICD-9 codes (401-401.9). * Independent in performing activities of daily living. * Ability to respond to SMS messages. Exclusion Criteria: * Diagnosis of Parkinson's disease. * Refusal to sign the informed consent form. * Diagnosis of cancer. * Mobility limitations that prevent engaging in physical activity. * Lack of a smartphone with internet access.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension

Contacts and locations

Locations

  • CUF

    Lisbon, Lisbon District, 1000, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.